UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2371-1
Program Prior Authorization/Medical Necessity
Medications Nemluvio® (nemolizumab-ilto)
P&T Approval Date 5/2025
Effective Date 9/1/2025
1. Background:
Nemluvio (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the
treatment of adults with prurigo nodularis and for the treatment of adults and pediatric patients
12 years of age and older with moderate to severe atopic dermatitis in combination with
topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately
controlled with topical prescription therapies.
2. Coverage Criteriaa:
A. Atopic Dermatitis
1. Initial Authorization
a. Nemluvio will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe atopic dermatitis
-AND-
(2) History of failure, contraindication, or intolerance to two of the following
therapeutic classes of topical therapies (document drug, date of trial, and/ or
contraindication to medication)^:
(a) Medium,high, or very-high potency topical corticosteroid [e.g., Elocon
(mometasone furoate), Synalar (fluocinolone acetonide), Lidex
(fluocinonide)]
(b) Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic
(tacrolimus)].*
(c) Eucrisa (crisaborole)*
-AND-
(3) Patient is not receiving Nemluvio in combination with either of the following
for treatment of the same indication:
(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent
(dupilumab), Ebglyss (lebrikizumab-lbkz)]
(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),
Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(4) Prescribed by one of the following:
(a) Dermatologist
(b) Allergist
(c) Immunologist
Authorization will be issued for 6 months.
2. Reauthorization
a. Nemluvio will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Nemluvio therapy
-AND-
(2) Patient is not receiving Nemluvio in combination with either of the following
for treatment of the same indication:
(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent
(dupilumab), Ebglyss (lebrikizumab-lbkz)]
(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR
(tofacitinib), Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]
-AND-
(3) Prescribed by one of the following:
(a) Dermatologist
(b) Allergist
(c) Immunologist
-AND-
(4) One of the following:
(a) Patient has achieved clear or almost clear skin
(Authorization of Nemluvio 30mg given every 8 weeks for 12 months)
(b) Patient has not yet achieved clear or almost clear skin
(Authorization of Nemluvio 30mg given every 4 weeks for 6 months)
B. Prurigo Nodularis
1. Initial Authorization
a. Nemluvio will be approved based on all of the following criteria:
© 2025 UnitedHealthcare Services, Inc.
2
(1) Diagnosis of prurigo nodularis
-AND-
(2) Patient has greater than or equal to 20 nodular lesions
-AND-
(3) History of failure, contraindication, or intolerance to previous prurigo nodularis
treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors, topical
capsaicin)
-AND-
(4) Patient is not receiving Nemluvio in combination with Dupixent for treatment
of the same indication
-AND-
(5) Prescribed by one of the following:
(a) Dermatologist
(b) Allergist
(c) Immunologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Nemluvio will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Nemluvio therapy
-AND-
(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment
of the same indication
-AND-
(3) Prescribed by one of the following:
(a) Dermatologist
(b) Allergist
(c) Immunologist
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
3
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
^Tried/failed alternative(s) are supported by FDA labeling.
* Elidel, Protopic/tacrolimus ointment, and Eucrisa require prior authorization.
Table 1: Relative potencies of topical corticosteroids
Class Drug Dosage Form Strength
(%)
Augmented betamethasone Ointment, gel 0.05
dipropionate
Very high
Clobetasol propionate Cream, foam, ointment 0.05
potency
Diflorasone diacetate Ointment 0.05
Halobetasol propionate Cream, ointment 0.05
Amcinonide Cream, lotion, ointment 0.1
Augmented betamethasone Cream, lotion 0.05
dipropionate
Betamethasone dipropionate Cream, foam, ointment, solution 0.05
Desoximetasone Cream, ointment 0.25
High Potency Desoximetasone Gel 0.05
Diflorasone diacetate Cream 0.05
Fluocinonide Cream, gel, ointment, solution 0.05
Halcinonide Cream, ointment 0.1
Mometasone furoate Ointment 0.1
Triamcinolone acetonide Cream, ointment 0.5
Betamethasone valerate Cream, foam, lotion, ointment 0.1
Clocortolone pivalate Cream 0.1
Desoximetasone Cream 0.05
Fluocinolone acetonide Cream, ointment 0.025
Medium
Flurandrenolide Cream, ointment, lotion 0.05
potency
Fluticasone propionate Cream 0.05
Fluticasone propionate Ointment 0.005
Mometasone furoate Cream, lotion 0.1
Triamcinolone acetonide Cream, ointment, lotion 0.1
Hydrocortisone butyrate Cream, ointment, solution 0.1
Lower-
Hydrocortisone probutate Cream 0.1
medium
Hydrocortisone valerate Cream, ointment 0.2
potency
Prednicarbate Cream 0.1
Alclometasone dipropionate Cream, ointment 0.05
Low potency Desonide Cream, gel, foam, ointment 0.05
Fluocinolone acetonide Cream, solution 0.01
Dexamethasone Cream 0.1
Lowest
Hydrocortisone Cream, lotion, ointment, solution 0.25, 0.5, 1
potency
Hydrocortisone acetate Cream, ointment 0.5-1
© 2025 UnitedHealthcare Services, Inc.
4
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class
• Supply limitations may be in place
4. References:
1. Nemluvio [package insert]. Dallas, TX: Galderma Laboratories, L.P., December 2024.
2. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic
dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am
Acad Dermatol. 2014; 71(1):116-32.
Program Prior Authorization/Medical Necessity - Nemluvio (nemolizumab-ilto)
Change Control
6/2025 New program.
© 2025 UnitedHealthcare Services, Inc.
5